Joyce, Kelsley EDelamere, JohnBradwell, SusieMyers, Stephen DavidAshdown, KimberlyRue, CarlaLucas, Samuel JeThomas, Owen DFountain, AmyEdsell, MarkMyers, FionaMalein, WillClarke, AlexLewis, Chrisopher TNewman, CharlesJohnson, BrianCadigan, PatrickWright, AlexanderBradwell, Arthurimray, chris2023-08-212023-08-212020-03-26BMJ Open Sport Exerc Med . 2020 Mar 26;6(1):e0006622055-764710.1136/bmjsem-2019-00066232341794http://hdl.handle.net/20.500.14200/1801With placebo, post-exercise α1-AGP levels were similar at sea level and altitude. Odds ratio (OR) for increased resting α1-AGP at altitude versus sea level was greater without losartan (2.16 times greater). At altitude, OR for reduced post-exercise α1-AGP (58% lower) was higher with losartan than placebo (2.25 times greater, p=0.059) despite similar pulse oximetry (SpO2) (p=0.95) between groups. Acetazolamide reduced post-exercise proteinuria by approximately threefold (9.3±9.7 vs 3.6±6.0 μg/min; p=0.025) although changes were not correlated (r=-0.10) with significant improvements in SpO2 (69.1%±4.5% vs 75.8%±3.8%; p=0.001).en© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Diseases & disorders of systemic, metabolic or environmental originHuman physiologySports medicineArticle